Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study / Nelli, F.; Giannarelli, D.; Fabbri, A.; Silvestri, M. A.; Berrios, J. R. G.; Virtuoso, A.; Marrucci, E.; Schirripa, M.; Mazzotta, M.; Onorato, A.; Panichi, V.; Topini, G.; Pessina, G.; Natoni, F.; Signorelli, C.; Chilelli, M. G.; Primi, F.; Ruggeri, E. M.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 33:7(2022), pp. 740-742. [10.1016/j.annonc.2022.04.002]